Evaluation of an association between loratadine and hypospadias - United States, 1997-2001

Morbidity and Mortality Weekly Report

Volumn 53, Issue 10, 2004, Pages 219-221

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; LORATADINE;

ARTICLE; CONGENITAL MALFORMATION; HUMAN; HYPOSPADIAS; MALE; NEWBORN; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ANTI-ALLERGIC AGENTS; HUMANS; HYPOSPADIAS; INFANT, NEWBORN; LORATADINE; MALE; UNITED STATES;

EID: 1542505407     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146-52.
2. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003:111:479-83.
3. Yoon PW, Rasmussen SA, Lynberg MC, et al. The national birth defects prevention study. Public Health Rep 2001;116(suppl 1):32-40.
4. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res Part A Clin Mol Teratol 2003:67:193-201.
5. Findlay SD. Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers and providers. Pharmacoeconomics 2001:19:109-19.
6. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
7. Food and Drug Administration. PDA approves OTC Claritin. FDA Consum 2003:37:3.
8. Schatz M, Zeiger RS. Diagnosis and management of rhinitis during pregnancy. Allergy Proc 1988;9:545-54.
9. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998:30:24-9, 46.